|
| Status |
Public on Dec 13, 2023 |
| Title |
BPTF inhibitor increases gastric cancer response to Erlotinib by epigenetically regulating c-MYC/PLCG1/pErk axis. |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
Expression profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
37863665 |
| |
| Submission date |
Apr 05, 2022 |
| Last update date |
Dec 14, 2023 |
| Contact name |
Li Fangyuan |
| E-mail(s) |
lifangyuan13@icloud.com
|
| Phone |
18701877783
|
| Organization name |
Shanghai Jiao Tong University
|
| Street address |
Ruijin Er road
|
| City |
Shanghai |
| State/province |
Shanghai |
| ZIP/Postal code |
021000 |
| Country |
China |
| |
|
| Platforms (2) |
| GPL10999 |
Illumina Genome Analyzer IIx (Homo sapiens) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (6)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE200181 |
BPTF inhibitor increases gastric cancer response to Erlotinib by epigenetically regulating c-MYC/PLCG1/pErk axis [ChIP-seq] |
| GSE200182 |
BPTF inhibitor increases gastric cancer response to Erlotinib by epigenetically regulating c-MYC/PLCG1/pErk axis [RNA-seq] |
|
| Relations |
| BioProject |
PRJNA823552 |
Less...
More...